Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy

研究成果: ジャーナルへの寄稿小調査

62 引用 (Scopus)

抜粋

The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted therapeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib, which target the intracellular tyrosine kinase domain of the EGFR. Furthermore, recent clinical and laboratory studies have identified molecular markers that have the potential to improve the clinical effectiveness of EGFR-targeted therapies. This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents.

元の言語英語
ページ(範囲)309-315
ページ数7
ジャーナルFEBS Journal
277
発行部数2
DOI
出版物ステータス出版済み - 1 1 2010
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

フィンガープリント Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用